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Symptoms of fatigue are often reported by patients in both the acute and chronic stages of recovery following a stroke. It is
commonly associated with low mood and sleep disturbances, but can arise in their absence. However, it has also been associated
with poorer long-term outcome and, as such, its aetiology warrants a greater understanding. There is convincing evidence that
inﬂammatory cascades and cytokine signalling precipitated by the infarct promote fatigue, and these pathways may harbour
therapeutic targets in its management.
1.Introduction
The repercussions of stroke can be devastating, given that it
cansuddenlyandpermanentlyimpairsomeofthemostbasic
functions we all take for granted, including our mobility,
speech, and eﬀective swallowing [1]. A national campaign by
TheStr ok eAssociation[2],termed“ActF.A.S.T.”,hasrecently
promoted the swift presentation to healthcare services for
anypatientsuspectedofhavingacutestroke,withassessment
for possible early thrombolysis. Gold standard care in hos-
pital involves admission to a designated stroke unit. Here,
a battery of investigations are performed to maximise sec-
ondary prevention, and a multidisciplinary team is able to
coordinate timely rehabilitation and attention to ongoing
medical, nutritional, and psychological needs. Amongst the
risks of developing anxiety states and disorders of (usually
low) mood, there exists a frequently occurring symptom of
poststroke fatigue (PSF) which can blight stroke patients’
recovery long after their physical disabilities have resolved.
Within the nervous system, fatigue can be centrally or
peripherally mediated [3]. The latter, for instance, is seen
in neuromuscular junction disorders, such as myasthenia
gravis, and does have deﬁnable parameters as a clinical
sign—these being diminished postexertional muscle power
on the Medical Research Council (MRC) scale and a 10%
decrement of motor end-plate potentials on electromyog-
raphy recordings. However, central fatigue is not so easily
deﬁned and symptomatically lies on a continuous spectrum
encompassing a whole host of ﬂuid terms including vitality,
motivation, and mood. It has been described in multiple
sclerosis patients as “a subjective lack of physical and/or
mental energy that is perceived by the individual or caregiver
to interfere with usual or desired activities” [4] and is thus,
by virtue of its own broad deﬁnition, a rather idiosyncratic
experience open to personal interpretation. This is reﬂected
by the large number of assessment scales or scoring systems
for fatigue to be found throughout the literature. To name
a few, there are linear analogue scales (visual analogue
scale, VAS [5–8]) and questionnaire-based systems (vitality
domain in the Short-Form 36, VIT SF-36 [9, 10]; fatigue
assessment scale, FAS [11]; checklist individual strength, CIS
[12]; fatigue severity scale, FSS [8, 13–16]; modiﬁed fatigue
impact scale, MFIS [17]) which do make it impossible to
standardise the data on fatigue. Nevertheless, despite PSF
research being comparative in its infancy, some important
studies have been conducted to help characterise the mecha-
nisms of onset and provide some understanding of methods
to diminish or, at least, control the symptoms for patients.
2.Poststroke FatigueandIts Associations
The symptom of fatigue following a stroke is commonly
found and has been described as one of the most diﬃcult2 ISRN Neurology
to cope with [18]. The negative impact of PSF can be felt
irrespective of whether the patient is at the younger [19]o r
older [20] end of the spectrum as it hampers their attempts
to return to normality and regain independence. It is tricky
to state a precise prevalence given that multiple studies have
assessedpatientsatverywide-rangingtimessincetheirstroke
onset, and each with diﬀerent measurements of fatigue.
However, at least 30% of patients, if not double that, will
experience it sometime in their recovery. It can be present
within weeks [15] and persist for many months [14, 21]o r
even years [6, 10, 13, 22] afterwards. Lerdal and colleagues
showed that within two weeks of stroke, 24% of patients
had severe fatigue on the FSS, 33% moderate, and 43%
mild or none [15]. They reported that greater fatigue was
related to a poorer physical function and symptoms of de-
pression, with a similar correlation being reported at one
year after stroke supported by Appelros [21]. However, as
time progresses, the association with the level of disability
becomesdisputed[12,13].Inaddition,patientswhosuﬀered
with premorbid fatigue had an increased chance of PSF [15];
the risk elsewhere was quoted at over 60% [8].
The association of PSF to the size of the infarct has not
been shown [10], but the site of the lesion may be relevant.
It has been suggested that lacunar infarcts located within the
basal ganglia, internal capsule [14], and infratentorial areas
[12] have been linked to an increased occurrence of PSF,
although there is no systematic review available as yet on
this. Interestingly, reduced thickness of the posterior parietal
cortex in patients with multiple sclerosis has been associated
with fatigue scores but, speciﬁcally, white matter lesions were
not [17]. Mead and coworkers, following people up for 64
months, did not ﬁnd an association between PSF and stroke
location but instead found increased PSF associated with
femalegenderandolderage[10].Harbisonetal.wereunable
to demonstrate any such age or gender association [16],
whereas Snaphaan and colleagues found that older age may
even be protective against fatigue following stroke [12].
There are clearly a lot of conﬂicting ﬁndings in the liter-
ature as regards risk factors for PSF. One rather less contro-
versial association with PSF is low mood [10, 12–14, 21–23].
Snaphaan and co-workers used the CIS to show that fatigue
at both two months and 18 months after stroke was present
inroughlyone-thirdofpatients(frequentlythesamepeople)
and had a statistically signiﬁcant association with scores on
the hospital anxiety depression scale [12]. Interestingly, there
was no residual physical impairment on indices of functional
status leading the authors to surmise that the PSF may be
more psychological than physical. Similarly, Park et al. found
that at thirty-two months after stroke there was a positive
correlation between the 30% of subjects who were fatigued
on the FSS and the 55% with symptoms of depression on a
self-report questionnaire, but again there was no convincing
relationship to functional impairment [13]. It is recognised
that aspects of fatigue and depression can be diﬃcult to tease
apart as mood assessment scales often include questions on
energy levels and fatigue, and vice versa. It also depends on
where the cut-oﬀ is taken. Tang et al. accordingly reported
increasedgeriatricdepressionscalescoresinfatiguedpatients
(also assessed by the FSS), despite the fact that patients
fulﬁlling the oﬃcial DSM-IV diagnosis of depression were
excluded from their cohort [14]. Glader et al. showed a
strong relationship between constant tiredness and always
beingdepressed[22],anditisdiﬃculttoknowwhetherthere
is some causality. Nevertheless, when patients who “often”
and “always” felt depressed were removed from analysis,
PSF was still a predictor for worse outcome, including more
dependence in activities of daily living and poorer general
health [22]. It was also a predictor for death, again inde-
pendently of depression. With the potential for PSF to have
implications for mortality as well as morbidity, it is vital for
us to further understand the possible mechanisms of fatigue
so that eﬀective management strategies can be devised.
3. Mechanisms of Fatigue
Fatigue does not only have a physical basis, but also compris-
esmentalandpsychologicalaspects[18]whichcanallcoexist
in the same patient. It may be that merely utilising executive
thinking to plan certain activities gives rise to a feeling of
fatigue and rapid exhaustion [23]. Although it is clear low
mood and, indeed, the degree of functional recovery do not
necessarily account for a sizable proportion of PSF, treating
depressive symptoms may make a valuable diﬀerence to the
emotional state and motivation of the patient. In a study
where all the patients had PSF on two assessment scales, the
selective serotonin reuptake inhibitor antidepressant ﬂuox-
etine failed to make any change to the fatigue scores after
three months’ therapy, yet dutifully improved poststroke
depression and emotional disturbance [8]. Therefore, other
factors precipitated by stroke must be responsible for PSF.
Stroke is not alone in being accompanied by fatigue
symptoms. Acute or chronic infections, long-term autoim-
mune conditions such as rheumatoid arthritis or systemic
lupus erythematosus, as well as malignant entities, particu-
larly following oncological treatments, are commonly asso-
ciated with fatigue. Even multiple sclerosis, which selectively
aﬀects the central nervous system (CNS), is notorious for
its association with fatigue. The common denominator is
activation of an inﬂammatory response. Inﬂammation pre-
cipitatessecretionofvariouscytokinesnecessaryforimmune
signalling including interleukin-6 (IL-6), interleukin-1 beta
(IL-1β), and tumour necrosis factor alpha (TNFα)a l lo f
which have sites of action within the central nervous sys-
tem [24]. They are thought to induce the so-called “sickness
behaviour” of decreased mood, lowered libido, poor appe-
tite, sleep disturbances, psychomotor slowing, and, impor-
tantly, fatigue [25, 26]. These attributes are considered evo-
lutionarily advantageous for overcoming injury and illness
and, ordinarily, would resolve once the insult has passed.
However, in situations where there is ongoing activation the
eﬀects are accordingly continued. Studies on cancer patients
who have chronic exposure to TNFα over time show that
two syndromes of sickness behaviour emerge: an early onset
but persistent “neurovegetative” state encompassing fatigue,
sleep problems, and psychomotor slowing followed later by
an additional “mood and cognitive” state in which there
are depression, anxiety, and impairment of memory andISRN Neurology 3
attention [25, 27, 28]. The latter syndrome tends to be the
one which responds to antidepressants whereas the former
doesnot[25]andmightexplainwhyﬂuoxetinedidnotaﬀect
chronic PSF but did improve mood [8].
Acute stroke similarly causes secretion of cytokines, che-
mokines, and proteases from activated microglia at the in-
farct epicentre accompanied by release of cytotoxic-free rad-
icals [29]. There is also early upregulation of Toll-like recep-
tors (TLRs) in neurons, which may be involved in proap-
optotic pathways, as well as in neighbouring microglia and
astrocytes [30]. Cascades downstream of these receptors en-
able the propagation of inﬂammation with production of
further cytokines [31] ,a n di tm a yb et h a tag r e a t e rr e s p o n s e
is mounted in older patients [25] for whom the majority of
strokes will befall. The components of sickness behaviour,
including fatigue, are then believed to be mediated through
neural, immune, and endocrine mechanisms. Dopaminergic
and serotonergic neurotransmitter systems are thought to
be aﬀected, with increased expression of their uptake trans-
porters,interferencewiththeirsynthesis,andpossiblyaltered
numbers of receptors [25]. Based on data collected in studies
of exercise-induced fatigue, it has been proposed that it is
the relative predominance of serotonin compared to dopam-
ine which precipitates fatigue [32, 33], and that exercise
training increases plasticity of dopaminergic circuitry lead-
ing to a more delayed onset over time. Cytokines may also
promote excitotoxic processes involving glutamatergic neu-
rotransmission causing cell death, blood brain barrier break-
down, and impaired homeostasis of astrocyte and neuron
metabolism [25, 34]. Production of neurotrophins, such as
brain-derived neurotrophic factor (BDNF) which is impor-
tant for synaptic plasticity and neuron survival both in times
of health and following nervous system injury, may be re-
duced [25]. A lack of BDNF may underlie the disorders of
psychomotor slowing and memory disturbance particularly
given that hippocampal functions rely heavily on its avail-
ability[35].Moreover,dopamine-secretingneuronsinvolved
in movement generation also widely express BDNF and its
receptor, TrkB. Both of these are upregulated within the CNS
by voluntary exercise and may underlie the postponement of
fatigue onset as mentioned above [32].
The hypothalamic-pituitary-adrenal (HPA) axis and the
autonomic nervous system, which enable communication
between the CNS and endocrine systems, oversee glucocor-
ticoid and catecholamine production, respectively, in times
of stress, and their activity can be modulated by cytokines as
interleukin receptors can be found throughout the HPA axis
and aﬀerent vagal ganglia [25, 26]. Short-term hyperactivity
of the HPA may be achieved in the acute phase, but after pro-
longed stimulation, there is a blunting of the normal diurnal
cortisol secretion curve with reduced glucocorticoid produc-
tion and onset of fatigue and depressive symptoms [25, 26].
Hypoactivity of the HPA axis owing to decreased corti-
cotrophin releasing hormone has been accordingly found in
patients with the chronic fatigue syndrome (CFS) as well as
in chronic autoimmune conditions [36]. Cortisol normally
has a negative feedback role on the sympathetic nervous
system and on inﬂammation, promoting humeral immune
responses in preference to cytokine production [25, 26].
Disordered sympathetic control, therefore, results and may
underpin the observations by Harbison and colleagues that
systemic hypertension above 145/90mmHg and diastolic
dips below 50mmHg on ambulatory blood pressure moni-
toring in chronic stroke patients is associated with PSF [16].
Again this has been seen also in patients with CFS [37].
IL-6 is associated with higher scores of fatigue [38]
and, when measured peripherally during the ﬁrst week after
stroke,itspeaklevelcorrelatespositivelywithinfarctvolume,
white blood cell count, and the acute phase response C-
reactive protein (CRP) and negatively with functional out-
come and mortality at 1 year [39]. Elevated CRP has itself
been associated with higher levels of PSF, particularly when
patients with depression were removed from the analysis,
although statistical signiﬁcance was not achieved [11]. It is
additionally raised in patients suﬀering with evident and
subclinical CFS, although it is acknowledged that CRP may
not be the best surrogate biomarker of CNS inﬂammation as
it is not speciﬁc to the condition [40]. Concurrent infections
are common in stroke victims and will aﬀect the blood CRP
level.Nevertheless,inﬂammatorysignallingishighlylikelyto
play a central part in generating PSF along with other forms
of fatigue, given that IL-6 is raised in cancer [38] and CFS
[41] patients too.
Disorders of sleep have been mentioned as part of sick-
ness behaviour [25, 26] and are commonly seen after stroke.
They have also been linked to PSF [9, 13, 21] which may
be improved when sleep issues are corrected [42]. Park and
co-workers found that patients’ FSS score correlated signif-
icantly with subjective sleeping problems like insomnia or
frequent waking [13]. A year or more after suﬀering a stroke
causing only upper limb deﬁcits, half of patients said they
were more sleepy than normal during daylight hours and
slept for longer periods at night, although the latter tended
to be less of an issue as time from stroke increased [9].
In addition, their sleepiness was unrelated to depression or
external stresses. It would be important to rule out an ob-
structivesleepapnoea,theaetiology ofwhichmaybeentirely
unrelated to stroke, but universal use of continuous airway
pressurecertainlydoesnotresolvePSFwhenitisabsent[43].
In fact poststroke sleep disorders and PSF may have their
originsnotonlyincytokinesignallingbutperhapsalsointhe
disruptionofcertainneuralnetworksasadirectconsequence
of the infarct. Staub and Bogousslavsky have proposed that
the ascending reticular activating system concerned with
maintaining tonic attention may become damaged by brain
stem and subcortical lesions leading to PSF [18] which was
inferred in the study by Tang and co-workers mentioned
earlier [14]. Nevertheless, some of the putative mechanisms
of PSF discussed provide a basis for the investigation of
eﬀective interventions in stroke patients.
4. Interventionsfor Poststroke Fatigue
A systematic review in 2008 concluded that insuﬃcient ev-
idence existed to recommend any single treatment for PSF
[44] and, to date, there continue to be no published guide-
lines. However, management guidelines for CFS have been4 ISRN Neurology
available from the National Institute for Health and Clinical
Excellence for several years [45] and may well be applicable
to PSF suﬀerers. Whereas the diagnosis for CFS relies on
there being new onset fatigue for at least four months with
no identiﬁable cause, we have discussed the overlap of symp-
toms between the two conditions, as well as the possible mu-
tual roles of cytokine and inﬂammatory signalling in their
generation.
The CFS guideline emphasises the need for patients to
recognise their limitations and set realistic goals for im-
provement, with assistance from graded exercise for aerobic
training and cognitive behavioural therapy (CBT) [45]. In-
deed, severalstudieshaveshowna relationship between poor
physical stamina and PSF [6, 7, 46], and aerobic ﬁtness, as
measured by peak oxygen consumption (VO2), is often re-
ducedinstrokesurvivors[47].Lewisandcolleaguesreported
that extensor power of the unaﬀected lower limb in fully
ambulatory chronic stroke patients was inversely propor-
tional to their level of PSF although, in this instance, VO2
wasnotfoundtocorrelatewithPSF[46].TsengandKluding,
conversely, did ﬁnd a negative correlation between PSF and
VO2 and that motor control particularly was an independent
predictor of PSF [6]. A preliminary trial of a 12-week treat-
ment termed “COGRAT” (Cognitive and Graded Activity
Training), which combines education, CBT, and increasing
exercise programmes, has demonstrated a signiﬁcant reduc-
tion of fatigue scores for patients with severe PSF [7]. The
authors recognise that a certain level of cognitive capability
and physical aptitude is necessary to participate in COGRAT
but that it fosters a more eﬀective coping strategy with which
patients can manage their fatigue [7]. A full clinical trial is
currently underway. Nevertheless, it is clear that maximising
cardiovascular ﬁtness appropriately is to be encouraged,
in addition to identifying other modiﬁable factors such as
depression, sleep apnoea, concurrent infective illness, or
biochemical abnormality which could be exacerbating PSF.
The contribution of pharmacotherapy for PSF is largely
unexplored and, as such, none are licensed for use in these
circumstances. One of the few drugs to be included in a
randomised controlled trial for PSF [44] has been the select-
ive serotonin reuptake inhibitor ﬂuoxetine but, as outlined
above, it improved depressive symptoms but not fatigue
scores [8]. Indeed, with a high serotonin to dopamine ratio
being implicated in central fatigue [32], enhancement of
dopaminergic neurotransmission and BDNF availability
m i g h tb em o r ea p p r o p r i a t et a r g e t s .T h ef r e ec o n c e n t r a t i o n
of the amino acid precursor to serotonin, tryptophan, is be-
lieved to be increased in the blood during exercise and may
contribute to central serotonin predominance and develop-
ment of fatigue [48]. Data in healthy subjects suggests that
administering more branched-chain amino acids during
exercise, and thus more competition for tryptophan uptake,
can prolong fatigue onset [48]. Interference with other neu-
rotransmitters, such as GABA with use of the GABAB re-
ceptor agonist baclofen, seems to have a similar eﬀect on
fatigue onset [32]a n dm a yt h u sh e l ps y m p t o m so fP S F .T h e
CNS stimulant modaﬁnil, which is currently approved in
narcolepsy and sleep apnoea, has also been piloted in a small
number of PSF and fatigued multiple sclerosis patients but
only seemed to beneﬁt the latter and those with lacunar
infarcts of the brainstem or thalamus [42]. Moreover, a
quarter of the participants dropped out due to side-eﬀect in-
tolerance. Studies using melatonin are encouraging but in-
conclusive [49]. A broad scope for further work trialling
these and otherdrugs speciﬁcallyforPSFis, therefore,prom-
ising.
Perhaps the most intriguing possibility for treating PSF
is agents which can attenuate ischaemic neuro-inﬂammation
and the development of the sickness behaviour syndromes.
IL-1ra is a competitive antagonist of the IL-1 receptor
whichis synthesised endogenouslyand blocks IL-1signalling
[50]. Administered peripherally in rodent models of middle
cerebral artery ischaemia, IL-1ra traverses the blood-brain
barrier to protect neurons from excitotoxic cell death and
reduced inﬂammatory damage from microglial activation
[51]. Importantly, it also improves functional recovery. Em-
sley and co-workers have shown that a 72-hour infusion of
recombinanthuman(rh)IL-1raissafeforuseinpatientsand,
when commenced within six hours of acute stroke, leads to
reduced levels of IL-6, CRP, and white blood cell count in the
days afterwards along with lower disability scores compared
to placebo at three months [50]. Although rh1L-1ra was
associated with a slight increase in bacterial infections, none
of these were serious. No mention was made of fatigue levels
in these patients but the study was powered really only for
proﬁlingsafety.Asuitablypoweredphase3studymaybeable
to provide supplementary data on PSF.
Activated protein C (APC) is another potentially emerg-
ing treatment for victims of stroke by virtue of its neuro-
protective, anticoagulant, and anti-inﬂammatory properties
and has the inherent ability to cross the BBB [52]. Its
eﬀects of particular signiﬁcance are that it reduces microglial
activation and suppresses the production of nuclear factor
kappa B (NF-κB) on which the subsequent expression of 1L-
1β,1 L - 6 ,a n dT N F α relies [53]. If PSF is indeed mediated by
inﬂammatory signalling, APC would hold great potential for
fatigue prevention as well as minimising functional deﬁcits
afterstroke.VersionsofrecombinantAPCcanbesynthesised
which possess diminished anticoagulant properties whilst
retaining their neuroprotective and anti-inﬂammatory ones
[52].
5. Conclusion
Fatigue after stroke is a common phenomenon which may
have a pathological basis resulting from the infarct, but not
dependent on its size or degree of functional loss. It is as-
sociated the least controversially with low mood and sleep
disturbances, but can arise in their absence. It is also asso-
ciated with poorer long-term outcome and it is, therefore,
essential for physicians in both primary and secondary care
to be able to recognise PSF. There is convincing evidence
that inﬂammatory cascades and cytokine signalling aﬀect the
neural, immune, and endocrine systems thereby precipitat-
ing fatigue symptoms, and these pathways may, therefore,
provide multiple targets for interventions aimed at reducing
PSF.ISRN Neurology 5
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